PMID: 7540858Jun 1, 1995Paper

C-myc amplification, double minutes and homogenous staining regions in a case of AML

British Journal of Haematology
C D FeganM Sweeney

Abstract

c-myc amplification is usually associated with lymphoid malignancies and Burkitt's lymphoma in particular. We present a case of AML with c-myc amplification which was associated with homogenous staining regions (hsr) and double minutes (dmin). The administration of GCSF following induction chemotherapy resulted in a marked increase in blast numbers. The GCSF was stopped and further courses of chemotherapy given, which resulted in complete remission. The patient relapsed 7 months after diagnosis and failed to go into a second remission with reinduction therapy. We conclude that c-myc amplification is a rare event in AML, but may be associated with chemotherapy resistance and a poor prognosis, are as dmins and hsr. Growth factors should be used with caution in these patients.

References

May 1, 1987·Cancer Genetics and Cytogenetics·B Dallapiccola
Oct 15, 1983·International Journal of Cancer. Journal International Du Cancer·Y S Li
Jul 1, 1993·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·C BarriosA Kreicbergs
Aug 1, 1993·Cancer Genetics and Cytogenetics·P W ThompsonH Brennan

❮ Previous
Next ❯

Citations

Dec 24, 2005·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Erich Gebhart
Feb 25, 2000·Cancer Genetics and Cytogenetics·P E CrossenM J Morrison
Nov 26, 1999·Proceedings of the National Academy of Sciences of the United States of America·F WienerS Mai
May 10, 2008·Cell Biology and Toxicology·R R BurbanoC Pessoa
Sep 18, 2008·Leukemia & Lymphoma·Sook Young BaeChang Kyu Lee
Feb 2, 2010·Cancer Genetics and Cytogenetics·Hélène BruyèreMonika Hudoba
Jul 16, 2009·Cancer Genetics and Cytogenetics·Kathleen C Rayeroux, Lynda J Campbell
Nov 10, 2010·Journal of Applied Toxicology : JAT·Edmundo L R PereiraRommel R Burbano
Jan 15, 2010·Human & Experimental Toxicology·T C R SilvaR R Burbano

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.